Literature DB >> 30302756

Molecular pharmacology of GPCRs.

Christopher J Langmead1, Roger J Summers1.   

Abstract

LINKED ARTICLES: This article is part of a themed section on Molecular Pharmacology of GPCRs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.21/issuetoc.
© 2018 The British Pharmacological Society.

Mesh：

Substances：

Year:  2018        PMID： 30302756      PMCID： PMC6177621          DOI： 10.1111/bph.14474

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  31 in total

Review 1.  Nuclear G protein signaling: new tricks for old dogs.

Authors:  Rhiannon Campden; Nicolas Audet; Terence E Hébert
Journal:  J Cardiovasc Pharmacol       Date:  2015-02       Impact factor: 3.105

Review 2.  GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.

Authors:  A D Mancini; V Poitout
Journal:  Diabetes Obes Metab       Date:  2015-02-24       Impact factor: 6.577

3.  Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist.

Authors:  Celine Valant; Lauren T May; Luigi Aurelio; Chung Hui Chuo; Paul J White; Jo-Anne Baltos; Patrick M Sexton; Peter J Scammells; Arthur Christopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-11       Impact factor: 11.205

Review 4.  The current state of GPCR-based drug discovery to treat metabolic disease.

Authors:  Kyle W Sloop; Paul J Emmerson; Michael A Statnick; Francis S Willard
Journal:  Br J Pharmacol       Date:  2018-03-25       Impact factor: 8.739

5.  Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs.

Authors:  J R Arch; A T Ainsworth; M A Cawthorne; V Piercy; M V Sennitt; V E Thody; C Wilson; S Wilson
Journal:  Nature       Date:  1984 May 10-16       Impact factor: 49.962

6.  The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.

Authors:  Lorraine A Fitzpatrick; Christine E Dabrowski; Gregory Cicconetti; David N Gordon; Socrates Papapoulos; Henry G Bone; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2011-05-18       Impact factor: 5.958

7.  G protein-coupled estrogen receptor inhibits vascular prostanoid production and activity.

Authors:  Matthias R Meyer; Natalie C Fredette; Matthias Barton; Eric R Prossnitz
Journal:  J Endocrinol       Date:  2015-08-24       Impact factor: 4.286

8.  Divergent effects of strontium and calcium-sensing receptor positive allosteric modulators (calcimimetics) on human osteoclast activity.

Authors:  Natalie A Diepenhorst; Katie Leach; Andrew N Keller; Patricia Rueda; Anna E Cook; Tracie L Pierce; Cameron Nowell; Philippe Pastoureau; Massimo Sabatini; Roger J Summers; William N Charman; Patrick M Sexton; Arthur Christopoulos; Christopher J Langmead
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739

Review 9.  International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers.

Authors:  Jean-Philippe Pin; Richard Neubig; Michel Bouvier; Lakshmi Devi; Marta Filizola; Jonathan A Javitch; Martin J Lohse; Graeme Milligan; Krzysztof Palczewski; Marc Parmentier; Michael Spedding
Journal:  Pharmacol Rev       Date:  2007-03       Impact factor: 25.468

10.  Sensitivity of cholecystokinin receptors to membrane cholesterol content.

Authors:  Aditya J Desai; Laurence J Miller
Journal:  Front Endocrinol (Lausanne)       Date:  2012-10-18       Impact factor: 5.555
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.